{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:38:36Z","timestamp":1753889916335,"version":"3.41.2"},"reference-count":36,"publisher":"IMR Press","issue":"3","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Background: Anti-GQ1b antibody syndrome referred to a clinical spectrum characterized by acute onset of ataxia, ophthalmoplegia and areflexia, while visual deterioration was rarely reported in terms of ocular disorders. This study aimed to describe the clinical characteristics of anti-GQ1b antibody syndrome with visual impairment. Methods: The database at the First Affiliated Hospital of Sun Yat-sen University was searched from 2014 to 2020. Patients with anti-GQ1b IgG were identified and divided into two groups according to the existence of optic neuropathy. Clinical and laboratory data of these subjects between the two groups were collected and analyzed. All patients were followed up by telephone to assess the outcome. Results: A total of 12 patients with seropositive anti-GQ1b antibody were included, 75% of which got antecedent infection. Of these cases, 3 showed visual deterioration accompanied by abnormal orbital magnetic resonance imaging or visual evoked potentials, and the other 9 didn\u2019t show any evidence of vision impairment. Patients in the optic neuropathy group presented prominent visual impairments as initial symptoms and were more likely to suffer from facial weakness. There were 4 patients in normal visual acuity group complaining of blurred vision due to intraocular muscle paralysis, which was distinguished by subsequent examination. The combination of glucocorticoids and intravenous immunoglobulin was applied to treat patients with optic neuropathy. Conclusions: This study provides strong evidence that anti-GQ1b antibody syndrome can exhibit visual impairment, which helps further expand the clinical spectrum of anti-GQ1b antibody syndrome. More attention should be paid to the physical and supplementary ophthalmological examination to explore the pathogenesis and treatment of anti-GQ1b antibody syndrome.<\/jats:p>","DOI":"10.31083\/j.jin2103081","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T09:30:31Z","timestamp":1649928631000},"source":"Crossref","is-referenced-by-count":1,"title":["Anti-GQ1b Antibody Syndrome with Visual Impairment: A Retrospective Case Series"],"prefix":"10.31083","volume":"21","author":[{"given":"Qing","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, 510080 Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated Guangren Hospital, School of Medicine, Xi'an Jiao tong University, 710004 Xi'an, Shaanxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Xing","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Function Examination, Zhongshan Hospital of Traditional Chinese Medicine, 528400 Zhongshan, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yao","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, 510080 Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Fan","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, 510080 Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, 510080 Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Jie","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, 510080 Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Susuki K, Yuki N, Hirata K. Fine specificity of anti-GQ1b IgG and clinical features. Journal of the Neurological Sciences. 2001; 185: 5\u20139.","key":"ref1","DOI":"10.1016\/S0022-510X(01)00464-6"},{"doi-asserted-by":"crossref","unstructured":"Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Annals of Neurology. 1992; 31: 677\u2013679.","key":"ref2","DOI":"10.1002\/ana.410310619"},{"doi-asserted-by":"crossref","unstructured":"Kusunoki S, Hitoshi S, Kaida K, Arita M, Kanazawa I. Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Annals of Neurology. 1999; 45: 400\u2013403.","key":"ref3","DOI":"10.1002\/1531-8249(199903)45:3<400::AID-ANA19>3.3.CO;2-P"},{"doi-asserted-by":"crossref","unstructured":"Odaka M. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. Journal of Neurology, Neurosurgery & Psychiatry. 2001; 70: 50\u201355.","key":"ref4","DOI":"10.1136\/jnnp.70.1.50"},{"doi-asserted-by":"crossref","unstructured":"Saul RF. Neuro-ophthalmology and the anti-GQ1b antibody syndromes. Current Neurology and Neuroscience Reports. 2009; 9: 379\u2013383.","key":"ref5","DOI":"10.1007\/s11910-009-0055-0"},{"doi-asserted-by":"crossref","unstructured":"Wakerley BR, Uncini A, Yuki N. Guillain\u2013Barr\u00e9 and Miller Fisher syndromes\u2014new diagnostic classification. Nature Reviews Neurology. 2014; 10: 537\u2013544.","key":"ref6","DOI":"10.1038\/nrneurol.2014.138"},{"doi-asserted-by":"crossref","unstructured":"Morrow SA, Fraser JA, Day C, Bowman D, Rosehart H, Kremenchutzky M, et al. Effect of Treating Acute Optic Neuritis with Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial. JAMA Neurology. 2018; 75: 690.","key":"ref7","DOI":"10.1001\/jamaneurol.2018.0024"},{"doi-asserted-by":"crossref","unstructured":"Conrad K, Schneider H, Ziemssen T, Talaska T, Reinhold D, Humbel R, et al. A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies. Annals of the New York Academy of Sciences. 2007; 1109: 256\u2013264.","key":"ref8","DOI":"10.1196\/annals.1398.031"},{"doi-asserted-by":"crossref","unstructured":"de Bruyn A, Poesen K, Bossuyt X, Heremans IP, Claeys T, Depuydt CE, et al. Clinical spectrum of the anti-GQ1b antibody syndrome: a case series of eight patients. Acta Neurologica Belgica. 2019; 119: 29\u201336.","key":"ref9","DOI":"10.1007\/s13760-019-01093-8"},{"doi-asserted-by":"crossref","unstructured":"Willison HJ, O\u2019Hanlon G, Paterson G, O\u2019Leary CP, Veitch J, Wilson G, et al. Mechanisms of action of anti-GM1 and anti-GQ1b ganglioside antibodies in Guillain-Barr\u00e9 syndrome. The Journal of Infectious Diseases. 1997; 176: S144\u2013S149.","key":"ref10","DOI":"10.1086\/513799"},{"unstructured":"Tettamanti G, Riboni L. Gangliosides and modulation of the function of neural cells. Advances in Lipid Research. 1993; 25: 235\u2013267.","key":"ref11"},{"doi-asserted-by":"crossref","unstructured":"Houliston RS, Koga M, Li J, Jarrell HC, Richards JC, Vitiazeva V, et al. A Haemophilus influenzae Strain Associated with Fisher Syndrome Expresses a Novel Disialylated Ganglioside Mimic. Biochemistry. 2007; 46: 8164\u20138171.","key":"ref12","DOI":"10.1021\/bi700685s"},{"doi-asserted-by":"crossref","unstructured":"Kimoto K, Koga M, Odaka M, Hirata K, Takahashi M, Li J, et al. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology. 2006; 67: 1837\u20131843.","key":"ref13","DOI":"10.1212\/01.wnl.0000244468.22377.6b"},{"doi-asserted-by":"crossref","unstructured":"Yoshino H, Maeda Y, King M, Cartwright MJ, Richards DW, Ariga T, et al. Sulfated glucuronyl glycolipids and gangliosides in the optic nerve of humans. Neurology. 1993; 43: 408\u2013411.","key":"ref14","DOI":"10.1212\/WNL.43.2.408"},{"doi-asserted-by":"crossref","unstructured":"Paparounas K. Anti-GQ1b ganglioside antibody in peripheral nervous system disorders: pathophysiologic role and clinical relevance. Archives of Neurology. 2004; 61: 1013\u20131016.","key":"ref15","DOI":"10.1001\/archneur.61.7.1013"},{"doi-asserted-by":"crossref","unstructured":"Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Research. 1997; 745: 32\u201336.","key":"ref16","DOI":"10.1016\/S0006-8993(96)01123-7"},{"doi-asserted-by":"crossref","unstructured":"Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barr\u00e9 syndrome: clinical and immunohistochemical studies. Neurology. 1993; 43: 1911\u20131917.","key":"ref17","DOI":"10.1212\/WNL.43.10.1911"},{"doi-asserted-by":"crossref","unstructured":"Saito K, Shimizu F, Koga M, Sano Y, Tasaki A, Abe M, et al. Blood-brain barrier destruction determines Fisher\/Bickerstaff clinical phenotypes: an in vitro study. Journal of Neurology, Neurosurgery, and Psychiatry. 2013; 84: 756\u2013765.","key":"ref18","DOI":"10.1136\/jnnp-2012-304306"},{"doi-asserted-by":"crossref","unstructured":"Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. Journal of Neurology, Neurosurgery, and Psychiatry. 2013; 84: 576\u2013583.","key":"ref19","DOI":"10.1136\/jnnp-2012-302824"},{"doi-asserted-by":"crossref","unstructured":"Lardone RD, Irazoqui FJ, Nores GA. Neurological disorders-associated anti-glycosphingolipid IgG-antibodies display differentially restricted IgG subclass distribution. Scientific Reports. 2020; 10: 13074.","key":"ref20","DOI":"10.1038\/s41598-020-70063-5"},{"doi-asserted-by":"crossref","unstructured":"Zhao T, Deng Y, Ding Y, Zhang R, Zhou C, Lin W. Anti-GQ1b antibody syndrome presenting with visual deterioration as the initial symptom: A case report. Medicine. 2020; 99: e18805.","key":"ref21","DOI":"10.1097\/MD.0000000000018805"},{"doi-asserted-by":"crossref","unstructured":"Kurihara M, Bannai T, Otsuka J, Kawabe Matsukawa M, Terao Y, Shimizu J, et al. Optic neuropathy and decorticate-like posture as presenting symptoms of Bickerstaff\u2019s brainstem encephalitis: a case report and literature review. Clinical Neurology and Neurosurgery. 2018; 173: 159\u2013162.","key":"ref22","DOI":"10.1016\/j.clineuro.2018.08.019"},{"doi-asserted-by":"crossref","unstructured":"Wen H. Acute bilateral vision deficit as the initial symptom in Guillain-Barre syndrome: a case report. Experimental and Therapeutic Medicine. 2018; 16: 2712\u20132716.","key":"ref23","DOI":"10.3892\/etm.2018.6465"},{"doi-asserted-by":"crossref","unstructured":"Chan JW. Optic neuritis in anti-GQ1b positive recurrent Miller Fisher syndrome. The British Journal of Ophthalmology. 2003; 87: 1185\u20131186.","key":"ref24","DOI":"10.1136\/bjo.87.9.1185"},{"doi-asserted-by":"crossref","unstructured":"Lamotte G, Laballe R, Dupuy B. Bilateral eyelid retraction, loss of vision, ophthalmoplegia: an atypical triad in anti-GQ1b syndrome. Revue Neurologique. 2014; 170: 469\u2013470.","key":"ref25","DOI":"10.1016\/j.neurol.2014.03.001"},{"doi-asserted-by":"crossref","unstructured":"Biotti D, Boucher S, Ong E, Tilikete C, Vighetto A. Optic neuritis as a possible phenotype of anti-GQ1b\/GT1a antibody syndrome. Journal of Neurology. 2013; 260: 2890\u20132891.","key":"ref26","DOI":"10.1007\/s00415-013-7094-9"},{"doi-asserted-by":"crossref","unstructured":"Robbins MS, Roth S, Swerdlow ML, Bieri P, Herskovitz S. Optic neuritis and palatal dysarthria as presenting features of post-infectious GQ1b antibody syndrome. Clinical Neurology and Neurosurgery. 2009; 111: 465\u2013466.","key":"ref27","DOI":"10.1016\/j.clineuro.2008.12.005"},{"doi-asserted-by":"crossref","unstructured":"Colding-J\u00f8rgensen E, Vissing J. Visual impairment in anti-GQ1b positive Miller Fisher syndrome. Acta Neurologica Scandinavica. 2001; 103: 259\u2013260.","key":"ref28","DOI":"10.1034\/j.1600-0404.2001.d01-31.x"},{"doi-asserted-by":"crossref","unstructured":"Yuki N, Hartung H. Guillain-Barr\u00e9 syndrome. The New England Journal of Medicine. 2012; 366: 2294\u20132304.","key":"ref29","DOI":"10.1056\/NEJMra1114525"},{"doi-asserted-by":"crossref","unstructured":"Lee S, Lim G, Kim JS, Oh S, Kim JK, Cha J, et al. Acute ophthalmoplegia (without ataxia) associated with anti-GQ1b antibody. Neurology. 2008; 71: 426\u2013429.","key":"ref30","DOI":"10.1212\/01.wnl.0000324266.95814.74"},{"doi-asserted-by":"crossref","unstructured":"Plomp JJ, Molenaar PC, O\u2019Hanlon GM, Jacobs BC, Veitch J, Daha MR, et al. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Annals of Neurology. 1999; 45: 189\u2013199.","key":"ref31","DOI":"10.1002\/1531-8249(199902)45:2<189::AID-ANA9>3.0.CO;2-T"},{"doi-asserted-by":"crossref","unstructured":"Boylu EE, To\u011frol RE, Senol MG, Ozda\u011f MF, Sara\u00e7o\u011flu M. Role of anti-GQ1B antibody in differential diagnosis of acute ophthalmoparesis. Neuropsychiatric Disease and Treatment. 2010; 6: 119\u2013122.","key":"ref32","DOI":"10.2147\/NDT.S8219"},{"doi-asserted-by":"crossref","unstructured":"Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. The Cochrane Database of Systematic Reviews. 2014; 2014: CD002063.","key":"ref33","DOI":"10.1002\/14651858.CD002063.pub6"},{"doi-asserted-by":"crossref","unstructured":"Hughes RAC, van Doorn PA. Corticosteroids for Guillain-Barr\u00e9 syndrome. The Cochrane Database of Systematic Reviews. 2012; 2012: CD001446.","key":"ref34","DOI":"10.1002\/14651858.CD001446.pub4"},{"doi-asserted-by":"crossref","unstructured":"Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barr\u00e9 syndrome. Lancet. 2016; 388: 717\u2013727.","key":"ref35","DOI":"10.1016\/S0140-6736(16)00339-1"},{"doi-asserted-by":"crossref","unstructured":"Beck RW, Cleary PA, Anderson MM, Keltner JL, Shults WT, Kaufman DI, et al. A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. New England Journal of Medicine. 1992; 326: 581\u2013588.","key":"ref36","DOI":"10.1056\/NEJM199202273260901"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/21\/3\/10.31083\/j.jin2103081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T15:40:26Z","timestamp":1732722026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/21\/3\/10.31083\/j.jin2103081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"alternative-id":["S0219-6352(22)00341-2"],"URL":"https:\/\/doi.org\/10.31083\/j.jin2103081","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"type":"print","value":"0219-6352"},{"type":"electronic","value":"1757-448X"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"article-number":"81"}}